ClinConnect ClinConnect Logo
Search / Trial NCT04402788

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Launched by NATIONAL CANCER INSTITUTE (NCI) · May 22, 2020

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

ClinConnect Summary

The RAPTOR Trial is a clinical study looking at whether adding radiation therapy to the usual treatment with atezolizumab can help patients with extensive stage small cell lung cancer. This type of cancer has spread beyond the lungs, and atezolizumab is a type of treatment that helps the immune system fight the cancer. The goal of the trial is to see if combining radiation with atezolizumab can help keep the cancer from growing or spreading for a longer time compared to using atezolizumab alone.

To be eligible for this trial, participants must have been diagnosed with extensive stage small cell lung cancer and have shown either a partial response or stable disease after receiving chemotherapy and atezolizumab. Patients should also have a good performance status, meaning they are generally able to carry out daily activities. Throughout the trial, participants will continue receiving atezolizumab and will also receive radiation therapy if they qualify. It’s important to note that women who can become pregnant must use effective contraception during the study and for several months afterward. This trial is currently recruiting participants, and those interested should speak with their healthcare provider to see if they qualify.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Any confirmation (cytologic, histologic, or pathologic) of extensive stage small cell lung cancer at any site, either primary or metastases
  • Partial response (PR) or stable disease (SD) after 4-6 cycles of etoposide/platinum (E/P) doublet plus atezolizumab by re-staging scans (positron emission tomography \[PET\]/computed tomography \[CT\] scan, diagnostic CT scan, magnetic resonance imaging \[MRI\] optional per treating physician); atezolizumab should continue through randomization. Patients must be randomized within 9 weeks of last dose of etoposide/platinum (if not receiving PCI) or 6 weeks from completion of prophylactic cranial irradiation (PCI)
  • NOTE: Patients must have at least 3 cycles of E/P plus atezolizumab. They can have one cycle of induction E/P without concurrent atezolizumab if unable to receive concurrent E/P combined with atezolizumab for all cycles of induction therapy
  • Patients must have measurable disease (per Response Evaluation Criteria in Solid Tumors \[RECIST\]) and 3 or fewer observable liver metastases and no evidence of progressive disease (per RECIST) at time of enrollment
  • At time of enrollment after induction E/P chemotherapy and atezolizumab, if there is a pleural effusion, patients will be eligible if thoracentesis is cytologically negative or if pleural fluid is too small a volume to effectively sample by thoracentesis and does not show increased metabolic activity on CT/PET imaging
  • * Appropriate stage for study entry based on the following diagnostic workup:
  • History/physical examination within 14 days prior to registration;
  • * Imaging within 42 days prior to registration to include:
  • MRI brain with contrast or CT brain with contrast
  • CT chest, abdomen and pelvis or whole body PET/CT scan any time after the fourth cycle of chemotherapy and prior to registration
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 14 days prior to registration
  • Absolute neutrophil count (ANC) \>= 1,000/cells/mm\^3 (within 14 days prior to registration)
  • Platelets \>= 75,000 cells/mm\^3 (within 14 days prior to registration)
  • Hemoglobin \>= 8 g/dL (within 14 days prior to registration)
  • Total bilirubin =\< 1.5 x upper limit of normal (ULN) (within 14 days prior to registration)
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3.0 x ULN (AST and/or ALT =\< 5 ULN for patients with liver involvement) (within 14 days prior to registration)
  • Alkaline phosphatase =\< 2.5 x ULN (=\< 5 ULN for patients with documented liver involvement or bone metastases) (within 14 days prior to registration)
  • Adequate renal function = Creatinine clearance \>=40 mL/min by the Cockcroft-Gault (C-G) equation: (within 14 days prior to registration)
  • Upfront radiation therapy of symptomatic metastatic site is permissible if causing symptoms such as pain or impending fracture
  • Patients with brain metastases are eligible after receiving whole brain radiation before enrollment (anytime during induction systemic therapy). Whole brain radiation can be delivered with hippocampal sparing or 3-D conformal technique. Patients with irradiated brain metastases are eligible if they are clinically stable from a neurological standpoint after completing radiotherapy (e.g. not having uncontrolled seizures) and do not require use of steroids above a dose of 10 mg of prednisone daily
  • For women of childbearing potential, a negative serum or urine pregnancy test within 14 days prior to registration.
  • * Note: Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
  • Women \< 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)
  • Women \>= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \> 1 year ago, had chemotherapy-induced menopause with last menses \> 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)
  • Patients positive for human immunodeficiency virus (HIV) on effective anti-retroviral therapy with undetectable viral load within 6 months and a stable regimen of highly active anti-retroviral (HAART) HIV-positive patients must have no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
  • Exclusion Criteria:
  • Metastatic disease invading the liver (\> 3 metastases), heart or \> 10 metastatic sites detectable after induction systemic therapy. Each visible bone metastasis on radiographic scan counts as one site
  • Patients with a concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen with atezolizumab or radiation
  • Prior radiotherapy in the thorax that would result in overlapping RT fields, unless the overlapping fields meet acceptable dose constraints for normal tissue
  • Active autoimmune disease, including, but not limited to: systemic lupus erythematosus; rheumatoid arthritis; inflammatory bowel disease (e.g. Crohn's, ulcerative colitis); vascular thrombosis associated with antiphospholipid syndrome; Wegener's granulomatosis; Sjogren's syndrome; Guillain-Barre syndrome; multiple sclerosis; vasculitis; or glomerulonephritis.
  • If the autoimmune disease is not active for over 3 years and the patient is not receiving immunosuppressive treatment such as methotrexate or steroids above a dose equivalent to 10 mg prednisone daily, the patient is eligible.
  • Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone are eligible
  • Patients with controlled type 1 diabetes mellitus on a stable insulin regimen are eligible
  • Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations are excluded only if they have active disease with acute exacerbation and on immunosuppressive medications within the 12 months prior to enrollment. They are eligible otherwise.
  • * Severe, active co-morbidity defined as follows:
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications;
  • Active tuberculosis;
  • Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease
  • Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen \[HBsAg\] test and a positive anti-HBc \[antibody to hepatitis B core antigen\] antibody test) are eligible
  • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA). (The HCV RNA test must be performed for patients who have a positive HCV antibody test)
  • Known immunosuppressive disease, for example history of bone marrow transplant or chronic lymphocytic leukemia (CLL);
  • Chronic obstructive pulmonary disease (COPD) requiring chronic oral steroid therapy of \> 10 mg prednisone daily or equivalent at the time of registration. Inhaled corticosteroids are not exclusionary;
  • Unstable angina and/or congestive heart failure requiring hospitalization within the last 3 months;
  • History of recent myocardial infarction within 6 months prior to registration.
  • Clinically significant interstitial lung disease
  • Pregnancy: Administration of atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment, and for 5 months (150 days) after the last dose of study agent. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Women who are breastfeeding and unwilling to discontinue
  • History of allogeneic organ transplant
  • Patients who have had immunotherapy-induced pneumonitis

About National Cancer Institute (Nci)

The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.

Locations

New Haven, Connecticut, United States

Lebanon, New Hampshire, United States

Milwaukee, Wisconsin, United States

Charleston, South Carolina, United States

Cleveland, Ohio, United States

Flint, Michigan, United States

Flint, Michigan, United States

Kalamazoo, Michigan, United States

Sioux Falls, South Dakota, United States

Peoria, Illinois, United States

Boston, Massachusetts, United States

Oklahoma City, Oklahoma, United States

Des Moines, Iowa, United States

Omaha, Nebraska, United States

La Crosse, Wisconsin, United States

Cleveland, Ohio, United States

Kalamazoo, Michigan, United States

Bozeman, Montana, United States

Houston, Texas, United States

Fort Collins, Colorado, United States

Gresham, Oregon, United States

Tualatin, Oregon, United States

Bryn Mawr, Pennsylvania, United States

Coon Rapids, Minnesota, United States

Urbana, Illinois, United States

Minneapolis, Minnesota, United States

Saint Paul, Minnesota, United States

Dayton, Ohio, United States

Effingham, Illinois, United States

Bethlehem, Pennsylvania, United States

Springfield, Illinois, United States

Lowell, Massachusetts, United States

Portland, Oregon, United States

Springfield, Illinois, United States

Media, Pennsylvania, United States

Troy, Michigan, United States

Pittsburgh, Pennsylvania, United States

Honolulu, Hawaii, United States

Rochester, New York, United States

Valhalla, New York, United States

Danville, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Salt Lake City, Utah, United States

Birmingham, Alabama, United States

Scottsdale, Arizona, United States

Tucson, Arizona, United States

Orange, California, United States

Jacksonville, Florida, United States

Atlanta, Georgia, United States

Savannah, Georgia, United States

Honolulu, Hawaii, United States

Chicago, Illinois, United States

Baltimore, Maryland, United States

Detroit, Michigan, United States

Southfield, Michigan, United States

Saint Cloud, Minnesota, United States

Columbia, Missouri, United States

Saint Louis, Missouri, United States

Bronx, New York, United States

New York, New York, United States

Syracuse, New York, United States

Winston Salem, North Carolina, United States

Bismarck, North Dakota, United States

Fargo, North Dakota, United States

Columbus, Ohio, United States

Hershey, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Wynnewood, Pennsylvania, United States

Burlington, Vermont, United States

Louisville, Kentucky, United States

Camden, New Jersey, United States

Bronx, New York, United States

Charlotte, North Carolina, United States

Canton, Ohio, United States

Cleveland, Ohio, United States

Columbus, Ohio, United States

Mayfield Heights, Ohio, United States

Allentown, Pennsylvania, United States

Morgantown, West Virginia, United States

Cape Girardeau, Missouri, United States

Aventura, Florida, United States

Honolulu, Hawaii, United States

Elmhurst, Illinois, United States

Fridley, Minnesota, United States

Memphis, Tennessee, United States

Berlin, Vermont, United States

Omaha, Nebraska, United States

Louisville, Kentucky, United States

Bethlehem, Pennsylvania, United States

Miami, Florida, United States

Royal Oak, Michigan, United States

Albuquerque, New Mexico, United States

Stony Brook, New York, United States

Sioux Falls, South Dakota, United States

Richmond, Virginia, United States

Sacramento, California, United States

Orlando, Florida, United States

Rochester, Minnesota, United States

Saint Louis, Missouri, United States

Bronx, New York, United States

Green Bay, Wisconsin, United States

Marshfield, Wisconsin, United States

Honolulu, Hawaii, United States

Portland, Oregon, United States

Miami Beach, Florida, United States

Decatur, Illinois, United States

Ottawa, Illinois, United States

Peoria, Illinois, United States

Peoria, Illinois, United States

Galesburg, Illinois, United States

Clive, Iowa, United States

Des Moines, Iowa, United States

Des Moines, Iowa, United States

Des Moines, Iowa, United States

Lansing, Michigan, United States

Des Moines, Iowa, United States

Maplewood, Minnesota, United States

Great Falls, Montana, United States

Sandusky, Ohio, United States

Sayre, Pennsylvania, United States

Wilkes Barre, Pennsylvania, United States

Spartanburg, South Carolina, United States

Kalamazoo, Michigan, United States

Bremerton, Washington, United States

Paoli, Pennsylvania, United States

Canandaigua, New York, United States

Atlanta, Georgia, United States

'Aiea, Hawaii, United States

Honolulu, Hawaii, United States

Honolulu, Hawaii, United States

Honolulu, Hawaii, United States

Galesburg, Illinois, United States

Wichita, Kansas, United States

Portland, Maine, United States

Worcester, Massachusetts, United States

Saginaw, Michigan, United States

Bemidji, Minnesota, United States

Reno, Nevada, United States

Akron, Ohio, United States

Cincinnati, Ohio, United States

Dayton, Ohio, United States

Franklin, Ohio, United States

Troy, Ohio, United States

Portland, Oregon, United States

Ephrata, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Sioux Falls, South Dakota, United States

Burlington, Vermont, United States

Roanoke, Virginia, United States

Minocqua, Wisconsin, United States

Rhinelander, Wisconsin, United States

Rice Lake, Wisconsin, United States

Stevens Point, Wisconsin, United States

Weston, Wisconsin, United States

Palo Alto, California, United States

San Francisco, California, United States

Colorado Springs, Colorado, United States

Savannah, Georgia, United States

Naperville, Illinois, United States

Cedar Rapids, Iowa, United States

Westerville, Ohio, United States

Wooster, Ohio, United States

Zanesville, Ohio, United States

York, Pennsylvania, United States

Bellingham, Washington, United States

Antigo, Wisconsin, United States

Wausau, Wisconsin, United States

Livonia, Michigan, United States

East Syracuse, New York, United States

Clackamas, Oregon, United States

Newberg, Oregon, United States

Munster, Indiana, United States

Albuquerque, New Mexico, United States

Boise, Idaho, United States

Charleston, West Virginia, United States

Duluth, Minnesota, United States

Hendersonville, North Carolina, United States

Independence, Ohio, United States

Tucson, Arizona, United States

Torrington, Connecticut, United States

Council Bluffs, Iowa, United States

Canton, Illinois, United States

Carthage, Illinois, United States

Eureka, Illinois, United States

Kewanee, Illinois, United States

Macomb, Illinois, United States

Peru, Illinois, United States

Princeton, Illinois, United States

Boise, Idaho, United States

Rockford, Illinois, United States

Greenville, South Carolina, United States

Greenville, South Carolina, United States

Atlanta, Georgia, United States

Colorado Springs, Colorado, United States

Weston, Florida, United States

Bloomington, Illinois, United States

Pekin, Illinois, United States

Scarborough, Maine, United States

Flint, Michigan, United States

Lansing, Michigan, United States

Mount Clemens, Michigan, United States

New York, New York, United States

Concord, North Carolina, United States

Lawton, Oklahoma, United States

Erie, Pennsylvania, United States

Harrisburg, Pennsylvania, United States

Greenville, South Carolina, United States

Greenwood, South Carolina, United States

Greer, South Carolina, United States

Seneca, South Carolina, United States

La Crosse, Wisconsin, United States

Wisconsin Rapids, Wisconsin, United States

Roseville, California, United States

Saint Johnsbury, Vermont, United States

York, Pennsylvania, United States

Wheeling, West Virginia, United States

Gettysburg, Pennsylvania, United States

Louisville, Kentucky, United States

Midland, Michigan, United States

Pennington, New Jersey, United States

Oklahoma City, Oklahoma, United States

Erie, Pennsylvania, United States

Jonesboro, Arkansas, United States

Sunnyvale, California, United States

Atlanta, Georgia, United States

Honolulu, Hawaii, United States

Lihue, Hawaii, United States

Fruitland, Idaho, United States

Meridian, Idaho, United States

Nampa, Idaho, United States

Twin Falls, Idaho, United States

West Des Moines, Iowa, United States

Bel Air, Maryland, United States

Clarkston, Michigan, United States

Lapeer, Michigan, United States

Albuquerque, New Mexico, United States

Monroe, North Carolina, United States

Shelby, North Carolina, United States

Fargo, North Dakota, United States

Columbus, Ohio, United States

Columbus, Ohio, United States

Strongsville, Ohio, United States

Monroeville, Pennsylvania, United States

Natrona Heights, Pennsylvania, United States

Rock Hill, South Carolina, United States

Vancouver, Washington, United States

Urbana, Illinois, United States

Springfield, Illinois, United States

Monroeville, Pennsylvania, United States

Beaver, Pennsylvania, United States

Greensburg, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Washington, Pennsylvania, United States

Fairfax, Virginia, United States

Great Falls, Montana, United States

Loveland, Colorado, United States

Sugar Land, Texas, United States

Newark, Delaware, United States

Newark, Delaware, United States

Rehoboth Beach, Delaware, United States

Caldwell, Idaho, United States

Nampa, Idaho, United States

Clive, Iowa, United States

West Des Moines, Iowa, United States

Brighton, Michigan, United States

Canton, Michigan, United States

Chelsea, Michigan, United States

Farmington Hills, Michigan, United States

Saginaw, Michigan, United States

West Branch, Michigan, United States

Voorhees, New Jersey, United States

Centerville, Ohio, United States

West Chester, Ohio, United States

Lewisburg, Pennsylvania, United States

Anchorage, Alaska, United States

Colorado Springs, Colorado, United States

Creston, Iowa, United States

Lexington, Kentucky, United States

Centralia, Illinois, United States

Danville, Illinois, United States

Decatur, Illinois, United States

Effingham, Illinois, United States

Mattoon, Illinois, United States

O'fallon, Illinois, United States

Louisville, Kentucky, United States

Brighton, Michigan, United States

Canton, Michigan, United States

Chelsea, Michigan, United States

Sainte Genevieve, Missouri, United States

Sullivan, Missouri, United States

Sunset Hills, Missouri, United States

Dayton, Ohio, United States

Clackamas, Oregon, United States

Conroe, Texas, United States

Houston, Texas, United States

League City, Texas, United States

Sturgeon Bay, Wisconsin, United States

Syracuse, New York, United States

Richmond, Virginia, United States

Novi, Michigan, United States

Southhaven, Mississippi, United States

Mansfield, Ohio, United States

Broomall, Pennsylvania, United States

Glen Mills, Pennsylvania, United States

Lebanon, Pennsylvania, United States

Gaffney, South Carolina, United States

Greenville, South Carolina, United States

Greer, South Carolina, United States

Union, South Carolina, United States

Eau Claire, Wisconsin, United States

Council Bluffs, Iowa, United States

Wexford, Pennsylvania, United States

Farmington, Utah, United States

Flower Mound, Texas, United States

Fort Worth, Texas, United States

Plano, Texas, United States

Sugar Land, Texas, United States

Menomonee Falls, Wisconsin, United States

West Bend, Wisconsin, United States

Carlisle, Pennsylvania, United States

Trumbull, Connecticut, United States

Des Moines, Iowa, United States

Louisville, Kentucky, United States

South Portland, Maine, United States

Columbia, Maryland, United States

Albert Lea, Minnesota, United States

Rochester, New York, United States

Phoenix, Arizona, United States

Chambersburg, Pennsylvania, United States

Coral Gables, Florida, United States

Deerfield Beach, Florida, United States

Plainfield, Illinois, United States

Glen Burnie, Maryland, United States

Charlotte, North Carolina, United States

Mckinney, Texas, United States

Jefferson Hills, Pennsylvania, United States

Phoenix, Arizona, United States

Bath, Maine, United States

Sanford, Maine, United States

Tawas City, Michigan, United States

Albuquerque, New Mexico, United States

Rock Hill, South Carolina, United States

New York, New York, United States

Fairfield, Connecticut, United States

Guilford, Connecticut, United States

North Haven, Connecticut, United States

Waterbury, Connecticut, United States

Waterford, Connecticut, United States

Albemarle, North Carolina, United States

Charlotte, North Carolina, United States

Charlotte, North Carolina, United States

Charlotte, North Carolina, United States

Stevens Point, Wisconsin, United States

Greenwich, Connecticut, United States

Bluffton, South Carolina, United States

Colorado Springs, Colorado, United States

Port Huron, Michigan, United States

Honolulu, Hawaii, United States

Easton, Pennsylvania, United States

Farrell, Pennsylvania, United States

'Aiea, Hawaii, United States

Mechanicsburg, Pennsylvania, United States

Oak Creek, Wisconsin, United States

Chadds Ford, Pennsylvania, United States

Washington, Illinois, United States

Farmington, Missouri, United States

Fort Collins, Colorado, United States

Greeley, Colorado, United States

Frankford, Delaware, United States

York, Pennsylvania, United States

Salt Lake City, Utah, United States

Bozeman, Montana, United States

The Woodlands, Texas, United States

Hamden, Connecticut, United States

Stamford, Connecticut, United States

Crown Point, Indiana, United States

Dyer, Indiana, United States

Hobart, Indiana, United States

Hobart, Indiana, United States

Munster, Indiana, United States

Valparaiso, Indiana, United States

Omaha, Nebraska, United States

Statesville, North Carolina, United States

Indiana, Pennsylvania, United States

Monroeville, Pennsylvania, United States

New Castle, Pennsylvania, United States

Washington, Pennsylvania, United States

Williamsport, Pennsylvania, United States

Newnan, Georgia, United States

Westerly, Rhode Island, United States

Vancouver, Washington, United States

Louisville, Kentucky, United States

Forest City, North Carolina, United States

Lincolnton, North Carolina, United States

Gastonia, North Carolina, United States

Pierre, South Dakota, United States

'Aiea, Hawaii, United States

Nampa, Idaho, United States

Springfield, Illinois, United States

Sheboygan, Wisconsin, United States

Yankton, South Dakota, United States

Matthews, North Carolina, United States

Des Moines, Iowa, United States

Allentown, Pennsylvania, United States

Lebanon, New Hampshire, United States

Nampa, Idaho, United States

Brighton, Michigan, United States

Chelsea, Michigan, United States

Dayton, Ohio, United States

Danville, Illinois, United States

Guilford, Connecticut, United States

Quakertown, Pennsylvania, United States

Greenville, Ohio, United States

Canton, Michigan, United States

Rhinelander, Wisconsin, United States

Stevens Point, Wisconsin, United States

Minocqua, Wisconsin, United States

Columbia, Missouri, United States

Stroudsburg, Pennsylvania, United States

Greenville, Pennsylvania, United States

Ankeny, Iowa, United States

Sunset Hills, Missouri, United States

O'fallon, Illinois, United States

Des Moines, Iowa, United States

Clive, Iowa, United States

Lansing, Michigan, United States

Rockford, Illinois, United States

Silverdale, Washington, United States

Saint Johnsbury, Vermont, United States

Dayton, Ohio, United States

Dayton, Ohio, United States

Royal Oak, Michigan, United States

Irvine, California, United States

Troy, Michigan, United States

Millville, Delaware, United States

Saginaw, Michigan, United States

Tawas City, Michigan, United States

Camillus, New York, United States

Southfield, Michigan, United States

Novi, Michigan, United States

Kalamazoo, Michigan, United States

Ankeny, Iowa, United States

Clive, Iowa, United States

Des Moines, Iowa, United States

Des Moines, Iowa, United States

Waukee, Iowa, United States

Union, South Carolina, United States

South Portland, Maine, United States

Portland, Maine, United States

Scarborough, Maine, United States

Patients applied

0 patients applied

Trial Officials

Quynh-Nhu Nguyen

Principal Investigator

NRG Oncology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials